Acute herpes zoster: Difference between revisions

Line 21: Line 21:


== Diagnosis==
== Diagnosis==
*Further evaluation if disseminated VZV
===Workup===
*Clinical diagnosis in most cases
*Consider viral Culture, antigen, PCR of vesicle fluid


*Immunocompromised
===Evaluation===
*If more than 3 or more dermatomes affected  
*Confirm that the patient does not have:
*If young, previously healthy adult-may be initial presentation with HIV
**[[Herpes zoster ophthalmicus]]
*Further evaluation for pneumonitis, hepatitis, encephalitis as clinically indicated
**[[Herpes zoster oticus]] (Ramsay Hunt syndrome)
*Atypical illness/severe disease
*Consider further evaluation for immunocompromized state (may be initial presentation of [[HIV]]) if:
**Viral Culture, antigen, PCR of vesicle fluid
**Disseminated
**If more than 3 or more dermatomes affected  
**Atypical illness/severe disease
*In immunocompromized patients consider further evaluation for:
**Pneumonitis
**[[Hepatitis]]
**[[Encephalitis]]


== Treatment  ==
== Treatment  ==

Revision as of 04:09, 27 July 2015

Background

  • Caused by Varicella Zoster Virus (VZV) causing Varicella (chicken pox) and later zoster (shingles)
  • Virus is dormant in dorsal root ganglion and reactivates causing characteristic rash in dermatomal distribution
  • Occurs once immunity to virus declines (elderly, immunosuppressed, post transplant, HIV)

Clinical Features

Herpes Zoster
  • Prodrome: Headache, malaise, photophobia
  • Antecedent pruritis, paresthesia, pain to dermatome 2-3 days prior to rash
  • Maculopapular rash (see below) progresses to vesicles, may coalesce to bullae, in dermatomal distribution lasting 10-15 days
  • Does not cross midline
  • Typically affects chest/face

Differential Diagnosis

Varicella zoster virus

Diagnosis

Workup

  • Clinical diagnosis in most cases
  • Consider viral Culture, antigen, PCR of vesicle fluid

Evaluation

  • Confirm that the patient does not have:
  • Consider further evaluation for immunocompromized state (may be initial presentation of HIV) if:
    • Disseminated
    • If more than 3 or more dermatomes affected
    • Atypical illness/severe disease
  • In immunocompromized patients consider further evaluation for:

Treatment

  1. Pain
    • PO narcotics
  2. Antiviral
    • Reduces risk/duration of postherpetic neuralgia
    • Immunocompetent patients:
      • Give acyclovir if <72hr of onset of rash or >72hr if new vesicles present/developing[1]
      • Acyclovir 800mg PO 5x/day x 7d
    • Immunosuppressed patients:
      • Give antiviral therapy at any stage of onset of rash
      • Acyclovir 10 mg/kg IV q8h OR 800mg PO 5x/day x 7d or foscarnet for acyclovir-resistant VZV, disseminated zoster, CNS involvement, ophthalmic involvement, advanced AIDS, recent transplant

Not Benificial

  • Steroids not shown to be beneficial

Disposition

  • Admit for disseminated VZ, CNS involvement, severely immunosupressed
  • Healing of lesions may take 4 or more weeks[2]

Complications

Prevention

  • Pt is contagious until lesions are crusted over
  • Consider varicella-zoster immunoglobulin to immunosupressed, pregnant, neonate contacts
  • Zoster vaccination if >60

See Also

References

  1. Cohen, J. Herpes Zoster. N Engl J Med 2013; 369:255-263. DOI: 10.1056/NEJMcp1302674
  2. Sampathkumar P, et al. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009; 84(3):274–280.